CoChat

CEREBROVASCULAR ACCIDENTS IN PATIENTS TREATED FOR CHOROIDAL NEOVASCULARIZATION WITH RANIBIZUMAB IN RANDOMIZED CONTROLLED TRIALS

Bressler, Neil M., Boyer, David S., Williams, David F., Butler, Steven, Francom, Steven F., Brown, Benton, Nucci, Flavia Di, Cramm, Timothy, Tuomi, Lisa L., Ianchulev, Tsontcho, Rubio, Roman G. · 2012 · Retina
Cited by 88

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

In Brief Purpose: To analyze cerebrovascular accidents (CVAs) pooled from large, randomized, controlled clinical trials of ranibizumab treatment for neovascular age-related macular degeneration. Methods: Events in five trials (FOCUS, MARINA, ANCHOR, PIER, and SAILOR) were analyzed using a standard safety monitoring process. Exact methods, stratified by study, were used to test for treatment differences based on odds ratios. A stepwise logistic regression model was fit to classify subjects' risk for CVA based on medical history. Treatment differences in CVA rates at 1 year or 2 years were evaluated within risk groups using stratified exact methods. Results: Pooled 2-year CVA rates were <3%; odds ratios (95% confidence intervals) for CVA risk were 1.2 (0.4–4.4) for ranibizumab 0.3-mg versus control, 2.2 (0.8–7.1) for 0.5 mg versus control, and 1.5 (0.8–3.0) for 0.5-mg versus 0.3-mg ranibizumab. No substantial increased risk of CVA for 0.5 mg versus 0.3 mg was identified in pooled analyses or any of the individual trials. In pooled analyses, the difference between 0.5-mg ranibizumab and control was larger (7.7 [1.2–177]) among high-risk CVA patients. Conclusion: This analysis provided some evidence, although not definitive, of a potential increased risk of CVA with ranibizumab versus control or with 0.5-mg versus 0.3-mg ranibizumab. Continued monitoring for CVA within clinical trials seems warrented. This analysis provided some evidence, although not definitive, of a potential increased risk of cerebrovascular accident with ranibizumab versus control or with 0.5-mg versus 0.3-mg ranibizumab. Continued monitoring for cerebrovascular accident within clinical trials seems warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/iae.0b013e31825db6ba

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 88

Metadata

Authors
Bressler, N. M., Boyer, D. S., Williams, D. F., Butler, S., Francom, S. F., Brown, B., Nucci, F. D., Cramm, T., Tuomi, L. L., Ianchulev, T., & Rubio, R. G.
Venue
Retina
Published
2012-10
Volume
32
Issue
9
Pages
1821-1828
ISSN
0275-004X (ISSN-L)
OpenAlex
W1968427420
Cited by
88
References
4
FWCI
12.31
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CEREBROVASCULAR ACCIDENTS IN PATIENTS TREATED FOR CHOROIDAL NEOVASCULARIZATION WITH RANIBIZUMAB IN RANDOMIZED CONTROLLED TRIALS. https://app.cochat.ai/papers/10.1097/iae.0b013e31825db6ba
The paper
Bressler, N. M., Boyer, D. S., Williams, D. F., Butler, S., Francom, S. F., Brown, B., Nucci, F. D., Cramm, T., Tuomi, L. L., Ianchulev, T., & Rubio, R. G. (2012). CEREBROVASCULAR ACCIDENTS IN PATIENTS TREATED FOR CHOROIDAL NEOVASCULARIZATION WITH RANIBIZUMAB IN RANDOMIZED CONTROLLED TRIALS. Retina. https://doi.org/10.1097/iae.0b013e31825db6ba

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.